Showing results (31-40 of 37) with videos related to
Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
Matrix Biology : Journal of the International Society for Matrix Biology|April 11, 2022
Pancreatic ductal adenocarcinoma cells employ integrin α6β4 to form hemidesmosomes and regulate cell proliferationJonathan D Humphries, Junzhe Zha, Jessica Burns, et al.British Journal of Cancer|July 20, 2016
Patterns of progression, treatment of progressive disease and post-progression survival in the New EPOC studySiân A Pugh, Megan Bowers, Alexandre Ball, et al.Nature Materials|September 14, 2021
A microenvironment-inspired synthetic three-dimensional model for pancreatic ductal adenocarcinoma organoidsChristopher R Below, Joanna Kelly, Alexander Brown, et al.Lancet (London, England)|January 29, 2017
Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trialJohn P Neoptolemos, Daniel H Palmer, Paula Ghaneh, et al.Annals of Surgery|October 26, 2017
The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal AdenocarcinomaPaula Ghaneh, Jorg Kleeff, Christopher M Halloran, et al.The Lancet. Gastroenterology & Hepatology|December 15, 2022
Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trialPaula Ghaneh, Daniel Palmer, Silvia Cicconi, et al.JAMA Surgery|September 5, 2019
Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy TrialRobert P Jones, Eftychia-Eirini Psarelli, Richard Jackson, et al.Pageof 4